Business
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a lead pipeline asset of Channel Therapeutics, a Pelthos subsidiary DURHAM, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announc
About this update from Pelthos Therapeutics Inc.
[{"type":"image","alt":"Pelthos Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Pelthos Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":179,"url":"https://media.zenfs.com/en/globenewswire.com/f94dd4c648565b20de109cac2516c355"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/k8zUsCvFBhGI4FW3YV9omg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1MQ--/https://media.zenfs.com/en/globenewswire.com/f94dd4c648565b20de109cac2516c355","width":300,"height":179}},"lazy":false},{"type":"text","content":"First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease","length":184,"tagName":"p"},{"type":"text","content":"CT2000 is a lead pipeline asset of Channel Therapeutics, a Pelthos subsidiary ","length":77,"tagName":"p"},{"type":"text","content":"DURHAM, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that the first patient has been dosed in a Phase 1b/2a clinical trial evaluating CT2000 as a potential treatment for eye pain. Pelthos’ subsidiary Channel Pharmaceutical Corporation (“Channel”) owns the rights to CT2000 and its NaV1.7 inhibitor pipeline and is conducting the clinical work through its Australian subsidiary.","length":564,"tagName":"p"},{"type":"text","content":""The successful dosing of the first patient is a meaningful step in advancing Channel’s pipeline of eye pain treatments,” said Scott Plesha, CEO of Pelthos. “While we remain focused on advancing our commercial-stage programs, the positive results from CT2000 animal efficacy studies suggest that the inhibition of NaV1.7 may have broad applications in treating different pain indications, including areas where new therapeutic options are needed.”","length":452,"tagName":"p"},{"type":"text","content":"The placebo-controlled Phase 1b/2a clinical trial will evaluate the safety and clinical efficacy of CT2000 eye drop formulation in patients with moderate to severe dry eye disease with chronic eye pain. The trial will be an adaptive design with a Phase 1 ascending dose study (with acute ocular pain measures) and a Phase 2a max...